354 related articles for article (PubMed ID: 29463421)
1. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.
Kovac M; Lal H; Cunningham AL; Levin MJ; Johnson RW; Campora L; Volpi A; Heineman TC;
Vaccine; 2018 Mar; 36(12):1537-1541. PubMed ID: 29463421
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials.
Willer DO; Oostvogels L; Cunningham AL; Gervais P; Gorfinkel I; Hyung Kim J; Talarico C; Wascotte V; Zahaf T; Colindres R; Schuind A;
Vaccine; 2019 Oct; 37(43):6262-6267. PubMed ID: 31537443
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
[TBL] [Abstract][Full Text] [Related]
5. Vaccine profile of herpes zoster (HZ/su) subunit vaccine.
Cunningham AL; Heineman T
Expert Rev Vaccines; 2017 Jul; 16(7):1-10. PubMed ID: 28486850
[TBL] [Abstract][Full Text] [Related]
6. Herpes zoster subunit vaccine for the prevention of herpes zoster.
Symoniak MR; Farrokh P; Gandhi MA; Slish JC
Am J Health Syst Pharm; 2018 Jun; 75(12):861-869. PubMed ID: 29880523
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
Lal H; Cunningham AL; Godeaux O; Chlibek R; Diez-Domingo J; Hwang SJ; Levin MJ; McElhaney JE; Poder A; Puig-Barberà J; Vesikari T; Watanabe D; Weckx L; Zahaf T; Heineman TC;
N Engl J Med; 2015 May; 372(22):2087-96. PubMed ID: 25916341
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
[TBL] [Abstract][Full Text] [Related]
9. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials.
Kim JH; Diaz-Decaro J; Jiang N; Hwang SJ; Choo EJ; Co M; Hastie A; Hui DSC; Irimajiri J; Lee J; Leung EM; Tang H; Tsuru T; Watson P; Wu Z; Yu CJ; Yuan Y; Zahaf T; Cunningham AL; Schuind A
Hum Vaccin Immunother; 2021 Jul; 17(7):2050-2057. PubMed ID: 33606577
[TBL] [Abstract][Full Text] [Related]
10. Vaccination: a new option to reduce the burden of herpes zoster.
Mick G
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.
Dagnew AF; Rausch D; Hervé C; Zahaf T; Levin MJ; Schuind A;
Rheumatology (Oxford); 2021 Mar; 60(3):1226-1233. PubMed ID: 32910152
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
[TBL] [Abstract][Full Text] [Related]
13. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
Cunningham AL; Heineman TC; Lal H; Godeaux O; Chlibek R; Hwang SJ; McElhaney JE; Vesikari T; Andrews C; Choi WS; Esen M; Ikematsu H; Choma MK; Pauksens K; Ravault S; Salaun B; Schwarz TF; Smetana J; Abeele CV; Van den Steen P; Vastiau I; Weckx LY; Levin MJ;
J Infect Dis; 2018 May; 217(11):1750-1760. PubMed ID: 29529222
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
15. Vaccination against Herpes Zoster and Postherpetic Neuralgia.
Oxman MN; Levin MJ;
J Infect Dis; 2008 Mar; 197 Suppl 2(Suppl 2):S228-36. PubMed ID: 18419402
[TBL] [Abstract][Full Text] [Related]
16. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
[TBL] [Abstract][Full Text] [Related]
17. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.
Oostvogels L; Heineman TC; Johnson RW; Levin MJ; McElhaney JE; Van den Steen P; Zahaf T; Dagnew AF; Chlibek R; Diez-Domingo J; Gorfinkel IS; Hervé C; Hwang SJ; Ikematsu H; Kalema G; Lal H; McNeil SA; Mrkvan T; Pauksens K; Smetana J; Watanabe D; Weckx LY; Cunningham AL
Hum Vaccin Immunother; 2019; 15(12):2865-2872. PubMed ID: 31216205
[TBL] [Abstract][Full Text] [Related]
18. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
[TBL] [Abstract][Full Text] [Related]
19. The herpes zoster subunit vaccine.
Cunningham AL
Expert Opin Biol Ther; 2016; 16(2):265-71. PubMed ID: 26865048
[TBL] [Abstract][Full Text] [Related]
20. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
